

***Artemisia annua*: trials are needed for COVID-19**

Faiz Ul Haq^{1, 2,*}, Muhammad Roman², Kashif Ahmad^{1, 5}, Saeed Ur Rahman³, Dr. Syed Murtaza Ali Shah², Naveed Suleman⁶, Sami Ullah⁴, Iftexhar Ahmad¹, Wajahat Ullah¹

1 Center for Biotechnology and Microbiology University of Swat, Pakistan

2 Department of Microbiology University of Health Sciences Lahore, Pakistan

3 Department of Nursing University of Health Sciences Lahore, Pakistan

4 Department of Forensic Science University of Health Sciences Lahore, Pakistan

5 Department of Microbiology, Hazara University, Pakistan

6 Department of Pharmacology University of Health Sciences Lahore, Pakistan

*For correspondence: faizulhaq553@gmail.com Cell# +923155747346

Keywords: Coronavirus: antiviral agents: Covid-19; *Artemisia annua*; bioactive compound; SARS-CoV-2

Running Title: *Artemisia annua* and COVID-19 treatment

Abstract

In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS-CoV-2 and disease called COVID-19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS-CoV-2. COVID-19 is great challenge for scientist across the globe. Bioactive compound present in *Artemisia annua* against, hepatitis B virus, bovine viral diarrhea virus and Epstein-Barr virus. *Artemisia annua* have shown significant activity against SARS coronavirus that occur in 2002. This agent is cheap and easily available and will be of great value if they have efficacy against SARS-COV-2. Scientific attention is needed towards these agent to address for the treatment of COVID-19.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ptr.6733.

Beginning in December 2019, an increasing number of cases of novel coronavirus, designated SARS-CoV-2, has caused worldwide outbreak of respiratory infection now termed coronavirus disease 2019 (COVID-19) (Cao *et al.*, 2020). As of March 26, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 462684 people and the death had reached over 20834 globally (WHO, 2020). Until yet, there are no vaccine and no specific antiviral agents for coronavirus infections, so it is a great challenge for scientists to find antiviral agent to treat this disease. Researcher endeavoring for antiviral agents, some of them are natural products, ritonavir, chloroquine phosphate, arbidol, ribavirin and traditional Chinese medicines that demonstrated preliminary efficacy against SARS-CoV, the virus that causes SARS in humans (Dong *et al.*, 2020). Scientific attention is needed towards efficacious therapies against COVID-19.

There are relevant information regarding therapies from the 2002-2003 outbreak of SARS CoV in China. The researcher tested in vitro antiviral activities of *Artemisia annua* whole plants preparation in ethanolic extract against SARS-CoV, with 50% effective concentration (EC50) value of 34.5 ± 2.6 $\mu\text{g/ml}$ and 50% cytotoxic concentration (CC50) of 1053 ± 92.8 $\mu\text{g/ml}$. The result afford strong support for the usage of *Artemisia annua* to treat SARS-CoV infectious diseases (Li *et al.*, 2005). In China, natural compounds has been frequently used in combination with conventional medicine to treat SARS. Some evidence demonstrated that the traditional herbal medicine is effective against SARS-CoV infectious diseases (Lin *et al.*, 2003).

Artemisinin is derivatives of *Artemisia annua* that have been commercialized as antimalarial drugs (Efferth *et al.*, 2008). As well as the value of artemisinin is not limited to the treatment of malaria, it is most promising natural products that is important candidates accounting for the antiviral effects (Karamoddini *et al.*, 2011). In addition *Artemisia annua* contain sterols that show virus inhibitory potential (Khan *et al.*, 1991).

Currently there are supportive and non-specific treatment to relieve patient symptom. For prophylaxis and treatment of virus the antiviral agent must be safe, adequate and cost should be preferably low. In China, most of the infected patient receiving traditional Chinese medicine for treatment of COVID-19 (Yang *et al.*, 2020). The subset methanolic extracts obtained from aerial parts of *A. annua* had the highest antiviral activity than acyclovir against Herpes Simplex virus type 1. Aerial subsets extracts of *A. annua* contain bioactive compound that may be an appropriate candidate for antiviral therapies (Karamoddini *et al.*, 2011). It has a history of being safe and easily available for therapies.

Pulmonary fibrosis are observed in SARS coronavirus-2 (SARS-CoV-2) infection with increased severity, mediated by Interleukin-1 (Conti *et al.*, 2020). Several studies suggesting that oxidative stress is associated with pulmonary diseases and it is likely that the consumption of natural antioxidant are effective in lung fibrosis (Day, 2008). *Artemisia annua* extract exhibit significant antioxidant activity that is most likely due to its high phenolic content (Ferreira *et al.*, 2010).

Artemisia annua derivatives, artesunate, is a promising novel drug to treat pulmonary fibrosis by inhibiting pro-fibrotic molecules associated with pulmonary fibrosis (Wang *et al.*, 2015). The rationale for testing antioxidants and anti-fibrotic effect in *Artemisia annua* is appealing that might play a key role in lung fibrosis.

The recent emergence of COVID-19 warrants the urgent development of potential antiviral therapies to protect population from high risk of infection (Mitjà & Clotet, 2020). There is immediate need for approved therapies to reduce the ongoing mortality, so it is important to emphasize the proven safety profiles of *Artemisia annua* for the treatment of COVID-19. Natural products found in *Artemisia annua* as chemical weapons to protect against infections by viruses, specifically herpes simplex virus type 1, hepatitis B virus, hepatitis C virus, bovine viral diarrhea virus and Epstein-Barr virus (Efferth *et al.*, 2008). Meanwhile this plant *Artemisia annua* is cheap and widely available, although the final analysis is therefore technically demanding. It will be of the great value to know the efficacy of these compound associated specifically SARS-COV-2. If a distinct antiviral compound are identified in *Artemisia annua*, it may be lead to active pharmaceutical compound production. These compound may contribute to reducing the use of high cost agent. The option of using *Artemisia annua* in the treatment of COVID-19 from SARS Cov-19 should be studied with attention in light of the previous studies. The experimental study on *Artemisia annua* may contribute to the identification of anti-coronavirus compounds that may successful and safe antiviral in in the treatment of COVID-19. We urge international scientific community to get focused on the efficacy of proposed agent against current ongoing pandemic. Further careful analysis of *Artemisia annua* for anti-coronavirus will be crucial before the discovery of new antiviral agent.

There is the possibility that studies on *Artemisia annua* preparations have been not carried according to more recent scientific qualitative standards for plant-derived products (Heinrich *et al.*, 2020). As the pandemic spreads, scientists around the globe are actively exploring drugs for combating an ongoing challenge. It is important to develop safe drugs for treatment of COVID-19. The efficacy and safety of *A. annua* in the therapy of COVID-19 is needed to be assessed in clinical trials.

Declarations

Author's contribution: All authors have contributed equally in this commentary.

Funding: The authors have not declared a specific grant for this study.

Competing interests: the authors declared no competing interest

References

- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. *New England Journal of Medicine*. 2020 Mar 18.
- Conti, P., Gallenga, C. E., Tetè, G., Caraffa, A., Ronconi, G., Younes, A., ... & Kritas, S. K. (2020). How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. *Journal of biological regulators and homeostatic agents*, 34(2).
- Day, B. J. (2008). Antioxidants as potential therapeutics for lung fibrosis. *Antioxidants & redox signaling*, 10(2), 355-370.
- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discoveries & Therapeutics*. 2020 Feb 29; 14(1):58-60.
- Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. *Clinical Infectious Diseases*. 2008 Sep 15;47(6):804-11.
- Ferreira, J. F., Luthria, D. L., Sasaki, T., & Heyerick, A. (2010). Flavonoids from *Artemisia annua* L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. *Molecules*, 15(5), 3135-3170.
- Heinrich, M., Appendino, G., Efferth, T., Fürst, R., Izzo, A. A., Kayser, O., ... & Viljoen, A. (2020). Best practice in research—overcoming common challenges in phytopharmacological research. *Journal of ethnopharmacology*, 246, 112230.
- Karamoddini MK, Emami SA, Ghannad MS, Sani EA, Sahebkar A. Antiviral activities of aerial subsets of *Artemisia* species against Herpes Simplex virus type 1 (HSV1) in vitro. *Asian Biomedicine*. 2011 Feb 1;5(1):63-8.
- Khan, M. A. A., Jain, D. C., Bhakuni, R. S., Zaim, M., & Thakur, R. S. (1991). Occurrence of some antiviral sterols in *Artemisia annua*. *Plant Science*, 75(2), 161-165.
- Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG, Li RS. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. *Antiviral research*. 2005 Jul 1;67(1):18-23.
- Lin L, Han Y, Yang ZM. Clinical observation on 103 patients of severe acute respiratory syndrome treated by integrative traditional Chinese and Western Medicine. *Zhongguo Zhong xi yi jie he zhi Zhongguo Zhongxiyi jiehe zazhi= Chinese journal of integrated traditional and Western medicine*. 2003 Jun;23(6):409-13.

- Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. *The Lancet Global Health*. 2020 Mar 19.
- Wang, C., Xuan, X., Yao, W., Huang, G., & Jin, J. (2015). Anti-profibrotic effects of artesunate on bleomycin-induced pulmonary fibrosis in Sprague Dawley rats. *Molecular medicine reports*, 12(1), 1291-1297.
- WHO. Coronavirus disease 2019 (COVID-19) situation report – 66. March 26, 2020. https://www.who.int/docs/default-source/coronaviruse/20200326-sitrep-66-covid-19.pdf?sfvrsn=81b94e61_2 (accessed March 27, 2020).
- Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. *Int J Biol Sci*. 2020;16(10):1708-17.